OM vs QTI

Outset Medical exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. Despite a strong current ratio of 6.67 suggesting short-term liquidity, the company suffers from catastrophic long-term price erosion (-99.5% over 5 years) and negative revenue growth. The combination of deep negative profit margins (-68.34%) and consistent insider selling suggests a lack of confidence in a turnaround. While analysts maintain a 'buy' rating with a $9.00 target, the deterministic data points to a high risk of further capital impairment.

The company exhibits critical financial weakness with a Piotroski F-Score of 1/9, indicating severe fundamental distress. Despite an extraordinary YoY revenue growth of 877.20%, the company remains deeply unprofitable with a profit margin of -111.40% and a history of massive earnings misses. Technical trends are overwhelmingly bearish, characterized by a 78.7% price collapse over the last six months. While short-term liquidity is stable, the combination of poor health scores and negative earnings progression suggests a high risk of further devaluation.